Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced Tuesday that the CF-002 Phase 2b study of lenabasum in patients with cystic fibrosis (CF) did not meet the primary endpoint of a statistically significant reduction in rate of new pulmonary exacerbations (PEx) per subject per 28 weeks.
from RTT - Biotech https://ift.tt/3ljIWTH
via IFTTT
No comments:
Post a Comment